局部晚期宫颈癌预后因素研究进展

Abstract
Figure/Table
References (39)
Related Citation (15)

Download: PDF (0 KB) HTML (48 KB)
Export: BibTeX | EndNote (RIS)

Abstract Cervical cancer is one of the most common malignant tumors in women all over the world.It can be asymptomatic at the early stage, therefore, most patients are in the middle and advanced stages (in phase IB2-IV by FIGO stages) at the time of consultation.The first choice of synchronous radiotherapy and chemotherapy is recommended by guidelines for patients with locally advanced cervical cancer (LACC).Although the short-term efficacy is fair, numerous long-term follow-up data indicate that the long-term prognosis is poor and it is prone to recurrence and metastasis.Analytical investigation on the prognostic factors of LACC patients contributes to making the best individualized treatment plan according to the specific conditions of patients.It is of great significance to improve the survival rate and quality of life of patients with LACC.This paper offers an overview of age, history of human papillomavirus (HPV) infection, hemoglobin index, tumor stages and differentiation, and treatment modes, etc.

Key words： Cervical cancer Prognosis Radiotherapy Drug treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HU Meng-ling
	ZHAO Jing-sheng

Cite this article:

HU Meng-ling,ZHAO Jing-sheng. Research progress of prognostic factors in locally advanced cervical cancer[J]. 中国当代医药, 2020, 27(23): 24-28.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I23/24

[1]	Li Y，Xu C.Human Papillomavirus-Related Cancers[J].Adv Exp Med Biol，2017，1018：23-34.
[2]	Arbyn M，Weiderpass E，Bruni L，et al.Estimates of incidence and mortality of cervical cancer in 2018：a worldwide analysis[J].Lancet Glob Health，2020，8（2）：e191-e203.
[3]	Datta NR，Samiei M，Bodis S.Radiation therapy infrastructure and human resources in low-and middle-income countries：present status and projections for 2020[J].Int J Radiat Oncol Biol Phys，2014，89（3）：448-457.
[4]	Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015[J].CA Cancer J Clin，2016，66（2）：115-132.
[5]	Moore KN，Java JJ，Slaughter KN，et al.Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation?an NRG oncology/gynecologic oncology group ancillary data analysis[J].Gynecol Oncol，2016，143（2）：294-301.
[6]	黄婷，李军，雷章，等.年龄与宫颈癌预后状况分析[J].中国现代医学杂志，2017，27（21）：84-88.
[7]	Shimamoto K，Satto T，Kitade S，et al.A study of treatments and outcomes in elderly women with cervical cancer[J].Eur J Obstet Gynecol Reprod Biol，2018，228：174-179.
[8]	De MC，Plummer M，Vignat J，et al.Worldwide burden of cancer attributable to HPV by site，country and HPV type[J].Int J Cancer，2017，141（4）：664-670.
[9]	De SS，Quint WG，Alemany L，et al.Human papillomavirus genotype attribution in invasive cervical cancer：a retrospective cross-sectional worldwide study[J].Lancet Oncol，2010，11（11）：1048-1056.
[22]	王一然，黄维，尹蕾，等.中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J].实用肿瘤学杂志，2018，32（5）：404-409.
[33]	周晖，白守民，林仲秋.《2019 NCCN 宫颈癌临床实践指南（第1版）》解读[J].中国实用妇科与产科杂志，2018，34（9）：1002-1009.
[34]	高岩，张新，王纯雁.同步放化疗治疗中晚期宫颈癌的疗效及毒副作用[J].中国肿瘤，2013，22（1）：73-76.
[10]	Reyes HD，Thiel KW，Carlson MJ，et al.Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers[J].Mol Diagn Ther，2014，18（2）：137-151.
[11]	Martinho O，Silva-Oliveira R，Cury FP，et al.HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer：Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors[J].Theranostics，2017，7（3）：717-732.
[12]	Ojesina AI，Lichtenstein L，Freeman SS，et al.Landscape of genomic alterations in cervical carcinomas[J].Nature，2014，506（7488）：371-375.
[13]	Lu H，Wu Y，Liu X，et al.A prospective study on neoadjuvant chemoradiotherapy plus anti-EGFR monoclonal antibody followed by surgery for locally advanced cervical cancer[J].Onco Targets Ther，2018，11：3785-3792.
[14]	Ueda A，Takasawa A，Akimoto T，et al.Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix[J].PLoS one，2017，12（8）：e0184123.
[15]	Minion LE，Tewari KS.Cervical cancer-state of the science：From angiogenesis blockade to checkpoint inhibition[J].Gynecol Oncol，2018，148（3）：609-621.
[16]	Crafton SM，Salani R.Beyond Chemotherapy：An Overview and Review of Targeted Therapy in Cervical Cancer[J].Clin Ther，2016，38（3）：449-458.
[17]	Mayumi S，Tetsuro O，Hiroaki K，et al.Serum vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer[J].Clin Ther，2019，24（12）：1612-1619.
[18]	Men H，Liang C，Yu M.Thrombocytosis as a prognostic factor in patients with renal cell carcinoma：a meta-analysis of literature[J].J Cancer Res Ther，2015，11（1）：67-72.
[19]	Zhang X，Lv Z，Yu H，et al.The clinicopathological and prognostic role of thrombocytosis in patients with cancer：a meta analysis[J].Oncol Lett，2017，13（6）：5002-5008.
[20]	Cao W，Yao X，Cen D，et al.Prognostic role of pretreatment thrombocytosis on survival in patients with cervical cancer：a systematic review and meta-analysis[J].World J Surg Oncol，2019，17（1）：132.
[21]	Miyatani K，Saito H，Kono Y，et al.Combined analysis of thepre-and postoperative neutrophil-lymphocyte ratio predicts the outcomes of atients with gastric cancer[J].Surg Today，2018，48（3）：300-307.
[23]	Barkati M，Fortin I，Mileshkin L，et al.Hemoglobin level in cervical cancer：a surrogate for an infiltrative phenotype[J].Int J Gynecol Cancer，2013，23（4）：724-729.
[24]	He YX，Wang Y，Cao PF，et al.Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy[J].Chin J Cancer，2016，35（1）：96.
[25]	Wang JZ，Mayr NA，Zhang D，et al.Sequential magnetic resonance imaging of cervical cancer：the predictive value of absolute tumor volume and regression ratio measured before，during，and after radiation therapy[J].Cancer，2010，116（21）：5093-5101.
[26]	Twu NF，Ou YC，Liao CI，et al.Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery：a Taiwanese Gynecologic Oncology Group （TGOG）study[J].Surg Oncol，2016，25（3）：229-235.
[27]	Nougaret S，Reinhold C，Alsharif SS，et al.Endometrial cancer：combined MR volumetry and diffusion-weighted imaging for assessment of myometrial and lymphovascular invasion and tumor grade[J].Radiology，2015，276（3）：797-808.
[28]	Jonska-Gmyrek J，Gmyrek L，Zolciak-Siwinska A，et al.Adenocarcinoma histology is a poor prognostic factor in locally advanced cervical cancer[J].Curr Med Res Opi，2019，35（4）：595-601.
[29]	Fujiwara H，Yokota H，Monk B，et al.Gynecologic Cancer InterGroup （GCIG）Consensus Review for Cervical Adenocarcinoma[J].Int J Gynecol Cancer，2014，24（9 Suppl 3）：S96-101.
[30]	Du XL，Tao J，Sheng XG，et al.Intensity-modulated radiation therapy for advanced cervical cancer：acomparison of dosimetricand clinical out comes with conventional radiotherapy[J].Gynecol oncol，2012，125（1）：151-157.
[31]	Lindegaard JC，Fokdal LU，Nielsen SK，et al.MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective[J].Acta Oncol，2013，52（7）：1510-1519.
[32]	Sturdza A，Potter R，Fokdal LU，et al.Image guided brachytherapy in locally advanced cervical cancer：Improved pelvic control and survival in RetroEMBRACE，a multicenter cohort study[J].Radiother Oncol，2016，120（3）：428-433.
[35]	Datta NR，Stutz E，Liu M，et al.Concurrent chemoradiotherapy vs.radiotherapy alone in locally advanced cervix cancer：a systematic review and meta-analysis[J].Gynecol Oncol，2017，145（2）：374-385.
[36]	Sarah MC，Ritu S.Beyond Chemotherapy：An Overview and Review of Targeted Therapy in Cervical Cancer[J].Clin Ther，2016，38（3）：449-458.
[37]	Minion LE，Tewari KS.Cervical Cancer-State of the Science：From Angiogenesis Blockade to Checkpoint Inhibition[J].Gynecol Oncol，2018，148（3）：609-621.
[38]	周晖，卢淮武，彭永排，等.《2015年NCCN 宫颈癌临床实践指南》解读[J].中国实用妇科与产科杂志，2015，31（3）：185-191.
[39]	Borcoman E，Le TC.Pembrolizumab in cervical cancer：latest evidence and clinical usefulness[J].Ther Adv Med Oncol，2017，9（6）：431-439.